Hemophilia and Hereditary Angioedema Enter a New Era with Non-Replacement and Gene Therapies
Shared Burden of Blood Coagulation and Vascular Edema
Hemophilia and Hereditary Angioedema (HAE) are two distinct diseases characterized by different symptoms, namely bleeding and acute edema, yet both are caused by the dysregulation of serine protease-based pathways. In the 1970s, treatment relied on the administration of plasma-derived products, which posed safety concerns and management challenges.
From Plasma to Recombinant and Non-Replacement Therapies
The introduction of recombinant technology enabled safer and more efficient preventive treatments for both diseases. Recently, non-replacement therapies, such as emicizumab, and rebalancing agents have been developed to prevent bleeding, while kallikrein/bradykinin pathway inhibitors prevent edema attacks. This shift in treatment paradigm has transformed the management of these diseases from acute event management to preventive care.
Gene and RNA Therapies: A New Era of Curative Treatments
Adeno-associated virus (AAV) vector-based gene therapy and lentiviral stem-cell approaches aim to provide sustained blood coagulation factor production in hemophilia patients, while antisense oligonucleotides (ASO) inhibit kallikrein to address the underlying cause of HAE. Emerging genome-editing approaches and biomarker- and genotype-driven strategies are expected to further enhance treatment efficacy.
A New Era of Personalized Medicine
As these innovations accumulate, personalized preventive and therapeutic strategies tailored to individual genetic profiles will become the norm. Ultimately, patients will no longer need to fear acute attacks, and their quality of life will significantly improve.
Hemophilia and hereditary angioedema (HAE) are rare monogenic disorders characterized by the dysregulation of serine protease-based biological pathways, that is, blood coagulation and the kallikrein-kinin system. Although clinical manifestations differ profoundly (bleeding vs angioedema), both diseases have recently undergone parallel therapeutic revolutions, shaped by advances in molecular biology and biotechnology. Early management in the 1970s relied for both diseases on the episodic administration of plasma-derived products, subsequently replaced by recombinant products that improved safety and feasibility of prophylaxis regimens. In the last 20 years, the development of nonreplacement products, such as emicizumab and rebalancing agents in hemophilia and kallikrein/bradykinin pathway inhibitors in HAE, shifted clinical practice from the episodic management of clinical events to their prevention. More recently, gene and RNA-based therapies are further transforming both diseases toward curative attempts: in hemophilia, adeno-associated virus vector-mediated gene therapy and lentiviral stem-cell approaches; in HAE, antisense oligonucleotide-mediated kallikrein suppression. Emerging genome-editing approaches and biomarker- and genotype-driven strategies are poised to further improve and personalize treatment. The therapeutic trajectories of rare diseases such as hemophilia and HAE illustrate how mechanistic insights enable the transition from the episodic management of acute events to long-term disease control, offering prospects for curative interventions.
Hemophilia and HAE pose significant risks to daily life due to bleeding and acute edema, respectively. New treatments offer preventive and curative approaches, greatly improving the quality of life for patients.